Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 1 of 3
ReNeuron focuses on exosome platform after restructuring
CustomEX is a platform that can be optimised for specific tissue targets and payloads
ReNeuron Group data points to effectiveness of its ground-breaking technology
The company attended an industry summit in Boston where it shared the findings of research on its CustomEx exosomes
ReNeuron Group names John Hawkins as chief financial officer in boardroom reshuffle
Hawkins joined ReNeuron in October 2014 as financial controller and was also appointed company secretary in June 2021
ReNeuron CEO: 'We have a great company that just needed a shake-up'
Catherine Isted joined the company just over a year ago - and there's been a whirlwind of activity since her arrival
ReNeuron recruits from within for CEO role
CFO Catherine Isted will take the hot seat after beating off external competition for the role
ReNeuron gets target upgrade after full year numbers
"The group is at an exciting point in its development with a strong stem cell platform grounded in IP"
ReNeuron focused fully on exosomes platform
Cash deposits currently are £14.5mln, giving a runway until mid-calendar 2023 at least
ReNeuron unveils board reshuffle as part of business refocus
Martin Walton joins as a non-executive director and "brings a wealth of relevant experience in the life sciences sector”
ReNeuron chief executive steps down after strategy change
Chairman Iain Ross will assume responsibility for running the company, supported by chief financial officer Catherine Isted
ReNeuron to focus on in-demand Exosome drug delivery technology
It is also looking to find a partner for its human retinal progenitor cells programme
ReNeuron makes progress with Fosun technology transfer
Fosun will spearhead the development of the CTX drug product for stroke disability in the Greater China region
ReNeuron re-appoints Corteling as vice president of research
Corteling has 24 years of experience in medical research and drug discovery, across the academia, biotechnology, and pharmaceutical industries
ReNeuron CEO says company is in the right place, at the right time, with the right technology
CEO Olav Hellebø was bullish about the potential of the company's exosomes research
ReNeuron jumps 13% as UCL study flags commercial potential of company's stem cell technology
Researchers found the pluripotent stem cells can be produced at 'mas scale' as a potential off-the-shelf product
ReNeuron inks collaboration deal with University College London
ReNeuron’s chief scientific officer, Dr Stefano Pluchino, said: “This collaboration is another strong development for ReNeuron which demonstrates the uniqueness and strong translational potential of our proprietary iPSC technology platform
ReNeuron treats first patient in mid-stage trials for eye disease candidate
The group also said that Catherine Isted has now joined the company as a chief financial officer
ReNeuron Group PLC shares soar on impressive data from latest breakthrough
The company's technology could help unlock treatments for stroke, Parkinson’s and Huntington’s diseases
ReNeuron hails “clear pre-clinical proof-of-concept” for exosomes technology
The ability to deliver therapeutic proteins to a part of the brain associated with stroke, Parkinson's Disease and Huntington's Disease could offer a breakthrough for doctors - though the company is at the very early stages of the R&D proce
Proactive news headlines: ReNeuron, Live Company, Coro Energy....
A summary of the small-cap stories on the Proactive website today
ReNeuron 'pleased to be back on track' with phase IIa eye disease trial
With the remaining people in the study expected to be treated by the end of the year, researchers are slated to present early efficacy data from the expansion cohort in the first quarter of 2022
ReNeuron appoints chief financial officer
Catherine Isted spent 12 years at partner level in two leading healthcare banking teams undertaking multiple initial public offerings and follow-on fundraisings
ReNeuron expects data in fourth quarter on two programmes
"Our exosome and iPSC platforms have also progressed well during the period"
ReNeuron appoints Iain Ross as non-executive chairman
"We welcome his support as we enter into a period where we expect to reach important, data-driven value inflection points across our programmes over the next 12 months," said CEO Olav Hellebø
ReNeuron now expects hRPC study data in fourth quarter
ReNeuron said it has temporarily halted dosing further patients until it finds the cause of an infection in the latest subject
Archive
Proactive news headlines: ReNeuron, Thor Mining, Critical Metals…
A look at some of the day's major headlines from the Proactive newswire
ReNeuron appoints new chief scientific officer
The cell-based therapies developer said Dr Stefano Pluchino will join the company with immediate effect on a part-time basis
ReNeuron unveils new collaborations, data findings on exosome technology platform
If the data collected from the new collaborations is positive, the company reckons it could seek potential out-licensing deals in six months or so
ReNeuron Group puts the focus on exosome technology
Reneuron has developed exosomes that can deliver a medically relevant payload of viral vaccines that might help in the fight against coronavirus.
ReNeuron begins search for new chief financial officer
“After twenty years at the company, and with the business now in a much stronger financial position, it is the right time for me to move on to new challenges,” said Michael Hunt
ReNeuron says phase IIa eye disease study "proceeding according to plan" as new group is dosed
Data from the clinical assessment will be presented later this year
ReNeuron jumps as US patent granted for hRPC therapy candidate
hRPC is designed to treat retinitis pigmentosa, an inherited disorder that causes blindness
ReNeuron raising up to £15mln to fund two key R&D programmes
The new investment that will be used to fund an expanded study on its treatment for a degenerative eye disease and to deliver proof-of-concept data from its exosome collaborations
ReNeuron Group says dosing has begun on expanded phase IIa trial of eye disease treatment
Earlier results from the clinical assessment of its hRPC cell therapy for the degenerative eye condition retinitis pigmentosa have been highly encouraging
ReNeuron confirms plan to reduce number of non-executive directors and appoint one from Obotritia Capital
Mark Evans, the chairman of significant ReNeuron shareholder Obotritia, will be appointed as a non-independent non-executive director of the company at the AGM on September 10
ReNeuron says US Patent and Trademark office has issued an allowance for its patent relating to human retinal progenitor cells
This notification of allowance in the US adds further intellectual property protection to the hRPC technology, which already has patent protection in a number of other major territories including Europe, Japan and Australia
ReNeuron up as it highlights significant near term opportunities, reduces full year losses
The biotech said its hRPC stem cell therapy candidate for retinal disease has delivered “positive and sustained top-line efficacy data” in an ongoing US Phase 1/2a clinical trial
ReNeuron treatment for degenerative eye condition “meaningful effect” for all points measured up to 18 months
Chief executive Olav Hellebø said: “The persistence of the observed clinical benefit is particularly encouraging”
ReNeuron Group agrees gene silencing collaboration with “major biotechnology company”
The two companies will use ReNeuron's exosomes technology to deliver the therapeutic
ReNeuron to focus on retinal disease and exosome-based technology programmes
This, chief executive Olav Hellebø said, provided the company “with significant near-term opportunities to deliver value-enhancing data and commercial partnerships”.
ReNeuron Group's CTX therapy shows early promise in treating Huntington's disease
New data items show for the first time that ReNeuron's CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease
ReNeuron jumps as it agrees research deal with unnamed “major pharmaceutical company” to develop emerging cell technology
The focus will be on ReNeuron's exosome technology
ReNeuron assessing potential of emerging cell technology in the coronavirus fight
It has developed a line of the human exosomes that can deliver a medically relevant payload; viral vaccines, for example
ReNeuron encouraged by 12-month data from cell therapy for degenerative eye disease
The update was provided alongside news the group had applied to the US regulator to add a further nine people to its phase I/IIa clinical study
ReNeuron says positive clinical data from Phase 2a trial of its CTX stem cell therapy candidate published in peer-reviewed journal
Data from the PISCES II study were originally presented by Professor Keith Muir at the American Heart Association International Stroke Conference in January 2018
Archive
Proactive news snapshot: ReNeuron, Metal Tiger, i3 Energy, Kodal Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron interims chart a period of significant progress; out-licence deal talks ongoing
"The period under review has been marked by significant progress across our various clinical and research programmes,” said Olav Hellebø, ReNeuron chief executive
Archive
Proactive news snapshot: ReNeuron, EQTEC, ADM Energy, Midatech Pharma …
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron to present data showing “significant advance” of CTX treatment
Data for the first time shows CTX could potentially produce non-donor-specific, 'off-the-shelf' stem cells as an alternative to existing treatments
ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases
Benjamin Yerxa, chief executive of the Foundation Fighting Blindness, said results from a recent clinical trial represented a major step forward for sufferers of a degenerative disease called retinitis pigmentosa
ReNeuron hails "clear signal" from retinitis pigmentosa trials
“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said
Proactive news snapshot: ReNeuron, Asiamet Resources, Base Resources...
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron hails heavy hitting new appointments to scientific advisory board
Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel have “world-class breadth of expertise” in the fields of ophthalmology and stem cell research, the company said
ReNeuron inks University of Cardiff collaboration
The venture will utilise ReNeuron's exosome-based drug delivery technology
Archive
Proactive news snapshot: Big Dish, Clinigen, European Metals
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron granted international patents over cell technology
The stem cell specialist now has 40 patents worldwide
Archive
Proactive news snapshot: Faron Pharmaceuticals, Pan African Resources, Iofina, Open Orphan …
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron creates role of business development and alliance director as deals pursued
Experienced biopharma director Nick Adams “will strengthen our business development capabilities and also be a dedicated resource for managing current and future licensing agreements”
Investments and investor services
FTSE 100 closes lower Friday after lacklustre week
The FTSE 250 went the other way and gained over 87 points on Friday
ReNeuron enjoys “transformational” year; eye disease trial data due in October
ReNeuron’s progress over the past year has been reflected in its share price, which has trebled since last March – the beginning of the company’s financial year
Investments and investor services
FTSE 100 closes lower again as European shares slide as mood sours
Footsie closed on Thursday nearly 21 points lower at 7,509.
Archive
Dart Group profits to rise in 2019 but analysts see weaker year ahead amid tough travel market
The day ahead includes full-year results from Dart Group and US inflation data
Archive
Kier Group is feeling the pressure ahead of Thursday’s trading update
Last month Kier issued a profit warning, so investors will be watching wearily as Thursday's trading update lands.
Archive
Barratt Developments and Bovis Homes to provide main building bricks in coming week
Aside from the two housebuilders, corporate updates in the coming week will also be delivered by retailers Ocado, Superdry and Dunelm
Archive
Proactive news snapshot: Westminster Group, Summit Therapeutics, Ethernity Networks, Hurricane Energy ...
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
K3 Business bemoans Brexit-related disruption
A look at some of the day's major movers, including Helical, Modern Water, Local Shopping REIT, Team17, TechFinancials, Westminster Group, Verditek and Pelatro
Archive
FTSE 100 closes firmly higher; Ashtead Group top dog
Britain's blue-chip benchmark closed up nearly 86 points at 7,443, while the FTSE 250 added over 154 points at 19,311
ReNeuron wins Breakthrough of the Year at 2019 Mediscience Awards
ReNeuron said it looks forward to "continuing to advance our clinical and business development activities in the months ahead".
Archive
Proactive news snapshot: Faron Pharmaceuticals, Highlands Natural Resources, Immotion Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: NetScientific , Metal Tiger, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
ANGLE points upwards after successful breast cancer trial outcome
A look at the day's major movers, including Karelian, UniVision, Cambria Africa, Bagir, Nautilus Marine, Stride Gaming and Patagonia Gold
Investments and investor services
FTSE 100 closes down after latest Trump trade war stunt
The Dow Jones suffered a 300 point fall in the first half hour of trading
Archive
Proactive news snapshot: EQTEC, Sound Energy, Sativa Investments...
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron well funded for pivotal period clinically and commercially
The cell therapy specialist has two clinical trials underway and is looking at partnerships or licensing deals for its three major programmes
Investments and investor services
Exillon Energy plunges after it calls in advisors to go over its accounts with a fine-toothed comb
A look at the day's major movers, including Bidstack, EU Supply, ReNeuron, Inspirit Energy, Prospex, Ferrexpo and Hastings Group
Archive
Proactive news snapshot: ReNeuron, Union Jack Oil, ANGLE, ECR Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
ReNeuron says eye disease patients see “sustained and further improvement” after cell treatment
The company has released the latest data from a Phase IIa study of people with a blindness-causing condition called retinitis pigmentosa
ReNeuron primed for further progress
ReNeuron Group PLC is at the forefront of stem cell science
ReNeuron shares up 30% after it strikes deal worth up to £80mln with Chinese pharma
Fosun Pharma is licensing the rights to the company’s CTX and hRPC cell therapy programmes
Archive
Proactive news snapshot: ReNeuron, AFC Energy, Collagen Solutions, AppScatter …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Seeing Machines, Erris Resources, BATM Advanced Communications …
A glance at some of the day's highlights from the Proactive Investors newswire
ContourGlobal wanted after making dividend commitment
A look at the day's major movers, including Photonstar, Starcom, Ncondezi, K3 Capital Group, Matomy Media, Tricorn Group and Prairie Mining
Investments and investor services
FTSE 100 closes in positive territory, boosted by better-than-expected US March jobs figures as Brexit uncertainty continues
"Small gains are the order of the day aside from in the UK, where again sterling weakness has allowed the FTSE 100 to register some reasonable gains," says Christ Beauchamp from IG
Investments and investor services
Andalas subsides after finance director resigns
A look at the day's major movers, including Gordon Dadds, Motif Bio, Proton Power, Regal Petroleum, Saga and Xeros Technology